Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment.
ex vivo model
immune checkpoint receptor
neuroendocrine liver metastases
soluble immunomodulators
tissue slices
tumour modeling
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
07
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
3
8
2022
Statut:
epublish
Résumé
Neuroendocrine liver metastases (LM-NEN) develop in a considerable proportion of patients with gastroenteropancreatic neuroendocrine neoplasms. There is a paucity of experimental models that accurately recapitulate this complex metastatic human liver microenvironment precluding scientific and clinical advancements. Here, we describe the development of a novel personalised immunocompetent precision cut tumour slice (PCTS) model for LM-NEN using resected human liver tissue. The histological assessment throughout the culture demonstrated that slices maintain viability for at least 7 days and retain the cellular heterogeneity of the original tumour. Essential clinical features, such as patient-specific histoarchitecture, tumour grade, neuroendocrine differentiation and metabolic capacity, are preserved in the slices. The PCTS also replicate the tumor-specific immunological profile as shown by the innate and adaptive immunity markers analysis. Furthermore, the study of soluble immune checkpoint receptors in the culture supernatants proves that these immunomodulators are actively produced by LM-NEN and suggests that this process is epithelium-dependent. This model can be employed to investigate these pathways and provides a powerful platform for mechanistic, immunological and pre-clinical studies.
Identifiants
pubmed: 35909511
doi: 10.3389/fendo.2022.909180
pmc: PMC9326114
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
909180Informations de copyright
Copyright © 2022 Doornebal, Harris, Riva, Jagatia, Pizanias, Prachalias, Menon, Preziosi, Zamalloa, Miquel, Zen, Orford, Eaton, Heaton, Ramage, Palma, Srirajaskanthan and Chokshi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9
pubmed: 18780869
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Clin Cancer Res. 2007 Aug 15;13(16):4704-12
pubmed: 17699847
J Cancer. 2016 Feb 05;7(5):484-9
pubmed: 26958083
Int J Hepatol. 2012;2012:819193
pubmed: 22518323
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Clin Cancer Res. 2018 May 1;24(9):2035-2043
pubmed: 29217527
J Cell Physiol. 2008 Aug;216(2):569-70
pubmed: 18384119
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235636
Asian Pac J Cancer Prev. 2012;13(8):4031-6
pubmed: 23098512
Endocr Relat Cancer. 2010 Dec 13;18(1):51-9
pubmed: 20959440
Nat Med. 2015 Nov;21(11):1364-71
pubmed: 26501191
J Gastrointest Surg. 2017 Nov;21(11):1821-1830
pubmed: 28730354
Br J Cancer. 2021 Jul;125(2):240-246
pubmed: 33837301
Hepatobiliary Surg Nutr. 2020 Aug;9(4):440-451
pubmed: 32832495
Oncoimmunology. 2021 May 25;10(1):1926762
pubmed: 34104542
Front Physiol. 2021 Mar 10;12:632502
pubmed: 33776793
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Gut. 2012 Jan;61(1):6-32
pubmed: 22052063
J Biol Chem. 1967 Jul 10;242(13):3239-41
pubmed: 6027798
PLoS One. 2015 Jul 20;10(7):e0133812
pubmed: 26192435
Adv Anat Pathol. 2019 Jan;26(1):69-74
pubmed: 30339548
Nat Protoc. 2010 Sep;5(9):1540-51
pubmed: 20725069
Sci Rep. 2020 Feb 25;10(1):3392
pubmed: 32099055
Sci Rep. 2018 Feb 28;8(1):3811
pubmed: 29491456
Neuroendocrinology. 2021;111(3):273-287
pubmed: 32241015
Alcohol Clin Exp Res. 2020 Apr;44(4):856-865
pubmed: 32020641
Sci Rep. 2019 Feb 14;9(1):2133
pubmed: 30765891
Cell. 2020 Nov 25;183(5):1420-1435.e21
pubmed: 33159857
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817395
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4471-6
pubmed: 15070742
HPB (Oxford). 2010 Dec;12(10):674-83
pubmed: 21083792
Front Endocrinol (Lausanne). 2021 Dec 23;12:710009
pubmed: 35002949
J Immunother. 2011 Apr;34(3):297-306
pubmed: 21389868
Neuroendocrinology. 2012;96(3):173-87
pubmed: 22538498
Pharmaceuticals (Basel). 2021 May 17;14(5):
pubmed: 34067837
Br J Cancer. 2019 Nov;121(11):966-972
pubmed: 31649320
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
BMC Cancer. 2019 Nov 1;19(1):1030
pubmed: 31675944
Nat Genet. 2019 Oct;51(10):1426-1427
pubmed: 31548718
Front Endocrinol (Lausanne). 2021 Mar 11;12:627819
pubmed: 33776923
Neuroendocrinology. 2021;111(3):217-236
pubmed: 32615560
Expert Rev Mol Diagn. 2019 Oct;19(10):895-904
pubmed: 31469965
BMC Cancer. 2016 Feb 09;16:78
pubmed: 26860465
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Clin Cancer Res. 2010 Nov 1;16(21):5365-6
pubmed: 20959409
Endocr Relat Cancer. 2018 Mar;25(3):367-380
pubmed: 29444910